{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:53:20Z","timestamp":1777686800126,"version":"3.51.4"},"reference-count":109,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:p>Huntington\u2019s disease (HD) is an autosomal dominant neurodegenerative disorder. The disease, characterized by motor, cognitive, and psychiatric impairments, is caused by the expansion of a CAG repeat in the huntingtin gene. Despite the discovery of the mutation in 1993, no disease-modifying treatments are yet available. Understanding the molecular and cellular mechanisms involved in HD is therefore crucial for the development of novel treatments. Emerging research has found that HD might be classified as a secondary tauopathy, with the presence of tau insoluble aggregates in late HD. Increased total tau protein levels have been observed in both HD patients and animal models of HD. Tau hyperphosphorylation, the main feature of tau pathology, has also been investigated and our own published results suggest that the protein phosphorylation machinery is dysregulated in the early stages of HD in R6\/1 transgenic mice, primarily in the cortex and striatum. Protein phosphorylation, catalysed by kinases, regulates numerous cellular mechanisms and has been shown to be dysregulated in other neurodegenerative disorders, including Alzheimer\u2019s disease. While it is still unclear how the mutation in the huntingtin gene leads to tau dysregulation in HD, several hypotheses have been explored. Evidence suggests that the mutant huntingtin does not directly interact with tau, but instead interacts with tau kinases, phosphatases, and proteins involved in tau alternative splicing, which could result in tau dysregulation as observed in HD. Altogether, there is increasing evidence that tau is undergoing pathological changes in HD and may be a good therapeutic target.<\/jats:p>","DOI":"10.3233\/jhd-230569","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:06:27Z","timestamp":1681819587000},"page":"1-13","source":"Crossref","is-referenced-by-count":14,"title":["Implications of Tau Dysregulation in Huntington\u2019s Disease and Potential for New Therapeutics"],"prefix":"10.1177","volume":"12","author":[{"given":"Isaline","family":"Mees","sequence":"first","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca M.","family":"Nisbet","sequence":"additional","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Hannan","sequence":"additional","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia"},{"name":"Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Renoir","sequence":"additional","affiliation":[{"name":"Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Australia"},{"name":"Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JHD-230569_ref1","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1074\/jbc.M110.199976","article-title":"Nuclear Tau, a key player in neuronal DNA protection","volume":"286","author":"Sultan","year":"2011","journal-title":"J BiolChem"},{"issue":"12","key":"10.3233\/JHD-230569_ref2","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/hipo.20712","article-title":"Essential role of tau phosphorylation in adult hippocampal neurogenesis","volume":"20","author":"Hong","year":"2010","journal-title":"Hippocampus"},{"issue":"4","key":"10.3233\/JHD-230569_ref3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1523\/JNEUROSCI.3191-12.2013","article-title":"Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy","volume":"33","author":"Holth","year":"2013","journal-title":"J Neurosci"},{"issue":"1633","key":"10.3233\/JHD-230569_ref4","doi-asserted-by":"publisher","first-page":"20130144","DOI":"10.1098\/rstb.2013.0144","article-title":"Microtubule-associated protein tau is essential for long-term depression in the hippocampus","volume":"369","author":"Kimura","year":"2014","journal-title":"Philos Trans R Soc B Biol Sci"},{"issue":"4","key":"10.3233\/JHD-230569_ref5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","article-title":"Multiple isoforms of human microtubule-associated protein tau:Sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease","volume":"3","author":"Goedert","year":"1989","journal-title":"Neuron"},{"issue":"2","key":"10.3233\/JHD-230569_ref6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","article-title":"Role of tau protein in both physiological and pathological conditions","volume":"84","author":"Avila","year":"2004","journal-title":"Physiol Rev"},{"issue":"2","key":"10.3233\/JHD-230569_ref7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0165-3806(03)00056-7","article-title":"Isoforms changes of tau protein during development in various species","volume":"142","author":"Takuma","year":"2003","journal-title":"Dev Brain Res"},{"issue":"12","key":"10.3233\/JHD-230569_ref8","doi-asserted-by":"publisher","first-page":"e84849","DOI":"10.1371\/journal.pone.0084849","article-title":"Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JHD-230569_ref9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res Bull"},{"issue":"4","key":"10.3233\/JHD-230569_ref10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/BST20120063","article-title":"The role of MAPT sequence variation in mechanisms of disease susceptibility","volume":"40","author":"Caffrey","year":"2012","journal-title":"Biochem Soc Trans"},{"issue":"24","key":"10.3233\/JHD-230569_ref11","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1093\/hmg\/ddl429","article-title":"Haplotype-specific expression of exon 10 at the human MAPT locus","volume":"15","author":"Caffrey","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.3233\/JHD-230569_ref12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.410410606","article-title":"Frontotemporal dementia and parkinsonism linked to chromosome A consensus conference","volume":"41","author":"Foster","year":"1997","journal-title":"Conference Participants. Ann Neurol"},{"issue":"3","key":"10.3233\/JHD-230569_ref13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: The therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.3233\/JHD-230569_ref14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1074\/jbc.M206236200","article-title":"Glycogen synthase kinase 3\u03b2 phosphorylates tau at both primed and unprimed sites: Differential impact on microtubule binding","volume":"278","author":"Cho","year":"2003","journal-title":"J Biol Chem"},{"issue":"13","key":"10.3233\/JHD-230569_ref15","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/ijms23137307","article-title":"Tau as a biomarker of neurodegeneration","volume":"23","author":"Holper","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.3233\/JHD-230569_ref16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/nan.12084","article-title":"Phosphorylation of tau protein at sites Ser396-404 is one of the earliest events in Alzheimer\u2019s disease and Down syndrome","volume":"40","author":"Mondrag\u00f3n-Rodr\u00edguez","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.3233\/JHD-230569_ref17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s004010100423","article-title":"Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer\u2019s disease","volume":"103","author":"Augustinack","year":"2002","journal-title":"Acta Neuropathol"},{"issue":"6762","key":"10.3233\/JHD-230569_ref18","doi-asserted-by":"publisher","first-page":"402615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"issue":"8","key":"10.3233\/JHD-230569_ref19","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","article-title":"Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation","volume":"22","author":"Liu","year":"2005","journal-title":"Eur J Neurosci"},{"issue":"1","key":"10.3233\/JHD-230569_ref20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"10.3233\/JHD-230569_ref21","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"10.3233\/JHD-230569_ref22","doi-asserted-by":"publisher","first-page":"580732","DOI":"10.3389\/fneur.2020.580732","article-title":"Targeting tau to treat clinical features of Huntington\u2019s disease","volume":"11","author":"Masnata","year":"2020","journal-title":"Front Neurol"},{"issue":"6","key":"10.3233\/JHD-230569_ref23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.410030616","article-title":"Huntington disease associated with Alzheimer disease","volume":"3","author":"McIntosh","year":"1978","journal-title":"Ann Neurol"},{"issue":"8-9","key":"10.3233\/JHD-230569_ref24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s007020050095","article-title":"Alzheimer-type lesions in Huntington\u2019s disease","volume":"105","author":"Jellinger","year":"1998","journal-title":"J Neural Transm"},{"issue":"7","key":"10.3233\/JHD-230569_ref25","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"issue":"8","key":"10.3233\/JHD-230569_ref26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/nm.3617","article-title":"Huntington\u2019s disease is afour-repeat tauopathy with tau nuclear rods","volume":"20","author":"Fern\u00e1ndez-Nogales","year":"2014","journal-title":"Nat Med"},{"key":"10.3233\/JHD-230569_ref27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3389\/fncel.2019.00574","article-title":"Altered levels and isoforms oftau and nuclear membrane invaginations in Huntington\u2019s disease","volume":"13","author":"Fern\u00e1ndez-Nogales","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"Suppl 1","key":"10.3233\/JHD-230569_ref28","doi-asserted-by":"publisher","first-page":"A44.1","DOI":"10.1136\/jnnp-2016-314597.125","article-title":"D26 Pathological tau signal in Huntington\u2019s disease - an in vivo [18F]-AV-PET imaging report","volume":"87","author":"Reetz","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.3233\/JHD-230569_ref29","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41374-018-0166-9","article-title":"Spectrum of tau pathologies in Huntington\u2019s disease","volume":"99","author":"Baskota","year":"2019","journal-title":"Lab Investig"},{"issue":"2","key":"10.3233\/JHD-230569_ref30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019sdisease","volume":"135","author":"St-Amour","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.3233\/JHD-230569_ref31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role inneurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Rev"},{"issue":"6","key":"10.3233\/JHD-230569_ref32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"10.3233\/JHD-230569_ref33","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.3233\/JHD-230569_ref34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40478-019-0764-9","article-title":"A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington\u2019s disease patients","volume":"7","author":"Liu","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"26","key":"10.3233\/JHD-230569_ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.M001475200","article-title":"Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells","volume":"275","author":"Wellington","year":"1983","journal-title":"J Biol Chem"},{"issue":"11","key":"10.3233\/JHD-230569_ref36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/nm.4199","article-title":"Caspase-2 cleavage of tau reversibly impairs memory","volume":"22","author":"Zhao","year":"2016","journal-title":"Nat Med"},{"issue":"9","key":"10.3233\/JHD-230569_ref37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.parkreldis.2011.06.010","article-title":"Increased levels of total tau protein in the cerebrospinal fluid in Huntington\u2019s disease","volume":"17","author":"Constantinescu","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.3233\/JHD-230569_ref38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.4161\/cib.21437","article-title":"Death or secretion?: The demise of a plausible assumption about CSF-tau in Alzheimer disease?","volume":"5","author":"Hall","year":"2012","journal-title":"Commun Integr Biol"},{"issue":"1","key":"10.3233\/JHD-230569_ref39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jnc.13719","article-title":"Cerebrospinal fluid total tau concentration predictsclinical phenotype in Huntington\u2019s disease","volume":"139","author":"Rodrigues","year":"2016","journal-title":"J Neurochem"},{"issue":"1","key":"10.3233\/JHD-230569_ref40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/hmg\/ddu456","article-title":"Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington\u2019s disease","volume":"24","author":"Gratuze","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.3233\/JHD-230569_ref41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/hmg\/ddu421","article-title":"Mutant huntingtin alters Tau phosphorylation and subcellular distribution","volume":"24","author":"Blum","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.3233\/JHD-230569_ref42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40478-018-0557-6","article-title":"Phosphorylation of different tau sites during progression of Alzheimer\u2019s disease","volume":"6","author":"Neddens","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"S3","key":"10.3233\/JHD-230569_ref43","doi-asserted-by":"crossref","first-page":"e060469","DOI":"10.1002\/alz.060469","article-title":"Brain derived biologically relevant tau oligomers","volume":"18","author":"Kayed","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"17","key":"10.3233\/JHD-230569_ref44","doi-asserted-by":"publisher","first-page":"5040","DOI":"10.1093\/hmg\/ddv224","article-title":"Decreased glycogen synthasekinase-3 levels and activity contribute to Huntington\u2019s disease","volume":"24","author":"Fern\u00e1ndez-Nogales","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.3233\/JHD-230569_ref45","doi-asserted-by":"publisher","first-page":"e2206","DOI":"10.1038\/cddis.2016.104","article-title":"GSK-3\u03b2-induced Tau pathology drives hippocampal neuronal cell death in Huntington\u2019s disease: Involvement of astrocyte-neuron interactions","volume":"7","author":"L\u2019Episcopo","year":"2016","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.3233\/JHD-230569_ref46","doi-asserted-by":"publisher","first-page":"8602","DOI":"10.1038\/s41598-017-09239-5","article-title":"In vivo regulation of glycogen synthase kinase 3\u03b2 activity in neurons and brains","volume":"7","author":"Krishnankutty","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.3233\/JHD-230569_ref47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.410250315","article-title":"An immunohistochemical investigation of the human neostriatum in Huntington\u2019s disease","volume":"25","author":"Goto","year":"1989","journal-title":"Ann Neurol"},{"issue":"6","key":"10.3233\/JHD-230569_ref48","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.3233\/JHD-230569_ref49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nsmb.2756","article-title":"Splicing factor SRSF6 promotes hyperplasia of sensitized skin","volume":"21","author":"Jensen","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"36","key":"10.3233\/JHD-230569_ref50","doi-asserted-by":"publisher","first-page":"30497","DOI":"10.1074\/jbc.M112.355412","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine\/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion","volume":"287","author":"Yin","year":"2012","journal-title":"J Biol Chem"},{"issue":"8","key":"10.3233\/JHD-230569_ref51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/embor.2012.90","article-title":"Loss of fused in sarcoma (FUS) promotes pathological Tau splicing","volume":"13","author":"Orozco","year":"2012","journal-title":"EMBO Rep"},{"issue":"10","key":"10.3233\/JHD-230569_ref52","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1074\/jbc.M705306200","article-title":"RNA-binding protein TLS is a major nuclear aggregate-interacting protein in Huntingtin exon 1 with expanded polyglutamine-expressing cells","volume":"283","author":"Doi","year":"2008","journal-title":"J Biol Chem"},{"key":"10.3233\/JHD-230569_ref53","doi-asserted-by":"publisher","first-page":"35236","DOI":"10.1038\/srep35236","article-title":"FUS\/TLS acts as an aggregation-dependent modifier of polyglutamine disease model mice","volume":"6","author":"Kino","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.3233\/JHD-230569_ref54","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","article-title":"Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease","volume":"91","author":"Alonso","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.3233\/JHD-230569_ref55","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.bbadis.2004.06.017","article-title":"Tau phosphorylation: Physiological and pathological consequences","volume":"1739","author":"Stoothoff","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JHD-230569_ref56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2012.06.003","article-title":"Axonal degeneration in Alzheimer\u2019s disease: When signaling abnormalities meet the axonal transport system","volume":"246","author":"Kanaan","year":"2013","journal-title":"Exp Neurol"},{"issue":"7","key":"10.3233\/JHD-230569_ref57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jnen\/61.7.640","article-title":"Intracellular deposition, microtubule destabilization, and transport failure: An \u201cearly\u201d pathogenic cascade leading to synaptic decline","volume":"61","author":"Bendiske","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5866","key":"10.3233\/JHD-230569_ref58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1126\/science.1152993","article-title":"Differential regulation of dynein and kinesin motor proteins by tau","volume":"319","author":"Dixit","year":"2008","journal-title":"Science"},{"issue":"11","key":"10.3233\/JHD-230569_ref59","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrm2782","article-title":"Traffic control: Regulation of kinesin motors","volume":"10","author":"Verhey","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"10.3233\/JHD-230569_ref60","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1128\/mcb.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.3233\/JHD-230569_ref61","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1523\/JNEUROSCI.0774-15.2016","article-title":"Tau-driven neuronal and neurotrophic dysfunction in a mouse model of early tauopathy","volume":"36","author":"Mazzaro","year":"2016","journal-title":"J Neurosci"},{"issue":"5529","key":"10.3233\/JHD-230569_ref62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.3233\/JHD-230569_ref63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1750-3639.2007.00111.x","article-title":"Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington\u2019s disease","volume":"18","author":"Zuccato","year":"2008","journal-title":"Brain Pathol"},{"issue":"3","key":"10.3233\/JHD-230569_ref64","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1460-9568.2006.04590.x","article-title":"Reduced expression of the TrkB receptor inHuntington\u2019s disease mouse models and in human brain","volume":"23","author":"Gin\u00e9s","year":"2006","journal-title":"Eur JNeurosci"},{"issue":"17","key":"10.3233\/JHD-230569_ref65","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1523\/JNEUROSCI.3920-03.2004","article-title":"Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor","volume":"24","author":"Baquet","year":"2004","journal-title":"J Neurosci"},{"issue":"38","key":"10.3233\/JHD-230569_ref66","doi-asserted-by":"publisher","first-page":"E5655","DOI":"10.1073\/pnas.1603020113","article-title":"TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington\u2019s disease","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.3233\/JHD-230569_ref67","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/tra.12610","article-title":"T-complex protein 1-ring complex enhances retrograde axonal transport by modulating tau phosphorylation","volume":"19","author":"Chen","year":"2018","journal-title":"Traffic"},{"issue":"1","key":"10.3233\/JHD-230569_ref68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019sdisease with the GSK-3 inhibitor tideglusib: A pilot study","volume":"33","author":"Del Ser","year":"2013","journal-title":"JAlzheimers Dis"},{"issue":"6","key":"10.3233\/JHD-230569_ref69","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer\u2019s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"522","key":"10.3233\/JHD-230569_ref70","doi-asserted-by":"publisher","first-page":"eaao6765","DOI":"10.1126\/scisignal.aao6765","article-title":"Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-","volume":"11","author":"Sen","year":"2018","journal-title":"Sci Signal"},{"issue":"12","key":"10.3233\/JHD-230569_ref71","doi-asserted-by":"publisher","first-page":"e52389","DOI":"10.1371\/journal.pone.0052389","article-title":"Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice","volume":"7","author":"Hosokawa","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JHD-230569_ref72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: Cohort analysis as modified primary outcome in a Phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"20","key":"10.3233\/JHD-230569_ref73","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1016\/j.bmcl.2016.08.092","article-title":"Design and synthesis of curcumin derivatives as tau and amyloid \u03b2 dual aggregation inhibitors","volume":"26","author":"Okuda","year":"2016","journal-title":"Bioorganic Med Chem Lett"},{"issue":"4","key":"10.3233\/JHD-230569_ref74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"31","key":"10.3233\/JHD-230569_ref75","doi-asserted-by":"publisher","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J Neurosci"},{"issue":"374","key":"10.3233\/JHD-230569_ref76","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.3233\/JHD-230569_ref77","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.omtn.2022.07.027","article-title":"Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies","volume":"29","author":"Easton","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"10.3233\/JHD-230569_ref78","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases","volume":"286","author":"Hickman","year":"2011","journal-title":"J Biol Chem"},{"issue":"4","key":"10.3233\/JHD-230569_ref79","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JHD-230569_ref80","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jconrel.2022.07.026","article-title":"Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy","volume":"349","author":"Bajracharya","year":"2022","journal-title":"J Control Release"},{"issue":"2","key":"10.3233\/JHD-230569_ref81","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.neuron.2013.07.046","article-title":"Anti-tau antibodies that block tau aggregate seeding invitro markedly decrease pathology and improve cognition in vivo","volume":"80","author":"Yanamandra","year":"2013","journal-title":"Neuron"},{"issue":"1","key":"10.3233\/JHD-230569_ref82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13024-017-0172-1","article-title":"Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: Characterization and therapeutic potency","volume":"12","author":"Agadjanyan","year":"2017","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.3233\/JHD-230569_ref83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","article-title":"Tau passive immunization inhibits not only tau but also A\u03b2 pathology","volume":"9","author":"Dai","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.3233\/JHD-230569_ref84","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"6","key":"10.3233\/JHD-230569_ref85","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"issue":"7561","key":"10.3233\/JHD-230569_ref86","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature14658","article-title":"Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy","volume":"523","author":"Kondo","year":"2015","journal-title":"Nature"},{"issue":"34","key":"10.3233\/JHD-230569_ref87","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J Neurosci"},{"issue":"5","key":"10.3233\/JHD-230569_ref88","doi-asserted-by":"publisher","first-page":"e0125614","DOI":"10.1371\/journal.pone.0125614","article-title":"Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models","volume":"10","author":"Sankaranarayanan","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.3233\/JHD-230569_ref89","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jnc.12821","article-title":"Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice","volume":"132","author":"Ittner","year":"2015","journal-title":"J Neurochem"},{"issue":"4","key":"10.3233\/JHD-230569_ref90","doi-asserted-by":"publisher","first-page":"e62402","DOI":"10.1371\/journal.pone.0062402","article-title":"Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity","volume":"8","author":"d\u2019Abramo","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.3233\/JHD-230569_ref91","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"10.3233\/JHD-230569_ref92","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.3233\/JAD-132477","article-title":"Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds","volume":"40","author":"Castillo-Carranza","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.3233\/JHD-230569_ref93","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomised, placebo-controlled trial","volume":"20","author":"H\u00f6glinger","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.3233\/JHD-230569_ref94","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: A randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.3233\/JHD-230569_ref95","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s12035-021-02698-y","article-title":"Quantitative phosphoproteomics reveals extensive protein phosphorylation dysregulation in the cerebral cortex of huntington\u2019s disease mice prior to onset of symptoms","volume":"59","author":"Mees","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"12","key":"10.3233\/JHD-230569_ref96","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1093\/hmg\/ddac001","article-title":"Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington\u2019s disease","volume":"31","author":"Mees","year":"2022","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.3233\/JHD-230569_ref97","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.2613","article-title":"Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export","volume":"18","author":"Lei","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.3233\/JHD-230569_ref98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1326-9-29","article-title":"Motor and cognitive deficits in aged tau knockout mice in two background strains","volume":"9","author":"Lei","year":"2014","journal-title":"Mol Neurodegener"},{"issue":"2","key":"10.3233\/JHD-230569_ref99","doi-asserted-by":"publisher","first-page":"e87605","DOI":"10.1371\/journal.pone.0087605","article-title":"Early structural and functional defects in synapses and myelinated axons in stratum lacunosum moleculare in two preclinical models for tauopathy","volume":"9","author":"Maurin","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.3233\/JHD-230569_ref100","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1074\/jbc.M409876200","article-title":"Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of tau-4R\/2N transgenic mice","volume":"280","author":"Terwel","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.3233\/JHD-230569_ref101","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ymthe.2022.01.020","article-title":"Passive immunization against phosphorylated tau improves features of Huntington\u2019s disease pathology","volume":"30","author":"Alpaugh","year":"2022","journal-title":"Mol Ther"},{"issue":"11","key":"10.3233\/JHD-230569_ref102","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.3390\/ijms22115911","article-title":"When good kinases go rogue: GSK3, p38 MAPK and CDKs as therapeutic targets for Alzheimer\u2019s and Huntington\u2019s disease","volume":"22","author":"D\u2019mello","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.3233\/JHD-230569_ref103","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.3233\/JAD-2012-129025","article-title":"GSK3 and tau: Two convergence points in Alzheimer\u2019s disease","volume":"33","author":"Hernandez","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 1","key":"10.3233\/JHD-230569_ref104","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.3233\/JAD-190851","article-title":"Role of phosphorylated tau and glucose synthase kinase 3 beta in Huntington\u2019s disease progression","volume":"72","author":"Sawant","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.3233\/JHD-230569_ref105","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/jnr.22184","article-title":"Mutant huntingtin and glycogen synthase kinase 3-\u03b2 accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington\u2019s disease","volume":"88","author":"Valencia","year":"2010","journal-title":"J Neurosci Res"},{"key":"10.3233\/JHD-230569_ref106","doi-asserted-by":"publisher","first-page":"105336","DOI":"10.1016\/j.nbd.2021.105336","article-title":"Inhibition of GSK-3 ameliorates the pathogenesis of Huntington\u2019s disease","volume":"154","author":"Rippin","year":"2021","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.3233\/JHD-230569_ref107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10020255","article-title":"Lithium and therapeutic targeting of GSK-3","volume":"10","author":"Snitow","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.3233\/JHD-230569_ref108","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.nbd.2012.06.026","article-title":"NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease","volume":"48","author":"Pouladi","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.3233\/JHD-230569_ref109","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/n2011.128","article-title":"Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington\u2019s disease","volume":"36","author":"Chiu","year":"2011","journal-title":"Neuropsychopharmacology"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-230569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:14Z","timestamp":1777452974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-230569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":109,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-230569","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}